tip manufacture refraction instruments, ophthalmic diagnostic instruments, visual acuity chart, ophthalmic unit, electric table
News
AbbVie and REGENXBIO Announce Eye Care Collaboration
Home News
AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie and REGENXBIO Announce Eye Care Collaboration

November 21, 2021
AbbVie photo

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) recently announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.